Abstract #36726 Ultrasensitive Assays for the Detection of Total and Phosphorylated Tau in Serum and Plasma

Anahit Aghvanyan, Jen Gillies, Galina Nikolenko, Laukik Sardesai, Vivek Chitnis, Lumu Manandar, Banita Tamot, Leo Serebryannyy, Mikayla Higgins, Leonid Dzantiev, Yeming Wang, Jane Zhang, Qi-Heng Yang, Seth Harkins, Jeff Debad, and Jacob N. Wohlstadter Meso Scale Discovery, Rockville, Maryland, USA

1 Abstract

Objectives: Increased Tau phosphorylation followed by the accumulation of Tau in cerebrospinal fluid (CSF) correlate with neurological disorders, including Alzheimer's Disease (AD). However, collection of CSF is invasive and inconvenient for use in screening of the disease. Serum and plasma are less invasive alternatives to CSF, but Tau levels in blood cannot be detected by standard immunoassay techniques. To address this, we have developed ultrasensitive assays for measuring total Tau and phosphorylated versions of Tau.


Methods: MSD's ultrasensitive assay format, S-PLEX[®], uses MSD's MULTI-ARRAY[®] electrochemiluminescence technology and allows for quantitation of biomarkers at fg/mL levels, up to 1000-fold lower than with standard immunoassay formats. Three Tau S-PLEX assays were developed: a total Tau (tTau) assay to quantitate all forms of Tau, and assays to quantitate Tau phosphorylated at two different sites (threonine 181 [pTau181] and threonine 231 [pTau231]). The assays were qualified to measure the three markers in serum and plasma samples.

Results: The new MSD[®] S-PLEX tTau and pTau(181) assays have a limit of detection (LOD) below 200 fg/mL and below 3000 fg/ml for pTau(231) based on full length Tau concentration. All assays have a dynamic range of at least 3 logs. The assays were used to measure levels of the biomarkers in samples from normal individuals and individuals with AD. Levels of total Tau were detectible in all normal samples and were elevated in disease samples. Phosphorylated Tau was detectable in a subset of normal samples and was elevated in a number of the AD samples.

Conclusions: Ultrasensitive assays for total Tau and phosphorylated versions of Tau have been developed using MSD's S-PLEX format, with improved sensitivity over standard immunoassay formats. The assays' improved sensitivity allows for quantitation of tTau and pTau in serum and plasma, and their utility has been demonstrated by measuring elevated levels in disease samples with


2 Methods


MSD's electrochemiluminescence detection technology uses SULFO-TAG[™] labels that emit light upon electrochemical stimulation initiated at the electrode surfaces of MULTI-ARRAY and MULTI-SPOT[®] microplates



Electrochemiluminescence Technology

- Minimal non-specific background and strong responses to analyte yield high signal-tobackground ratios.
- The stimulation mechanism (electricity) is decoupled from the response (light signal), minimizing matrix interference.
- Only labels bound near the electrode surface are excited, enabling non-washed assays.
- Labels are stable, non-radioactive, and directly conjugated to biological molecules.
- Emission at ~620 nm eliminates problems with color quenching.
- Multiple rounds of label excitation and emission enhance light levels and improve
- sensitivity. • Carbon electrode surface has 10X greater binding capacity than polystyrene wells.
- Surface coatings can be customized.









	Total Tau441 Concen.	Total Tau				pTau (181)				pTau (231)			
Sample		Phosphorylated Tau Calibrator		Non- phosphorylated Tau Calibrator		Phosphorylated Tau Calibrator		Non- phosphorylated Tau Calibrator		Phosphorylated Tau Calibrator		Non- phosphorylated Tau Calibrator	
	(pg/mL)	ECL	%CV	ECL	%CV	ECL	%CV	ECL	%CV	ECL	%CV	ECL	%CV
Cal-1	2,000	1,248,209	1.1	1,231,394	2.1	260,648	0.6	251	4.4	42,406	3.2	243	2.7
Cal-2	500	675,095	0.8	651,122	3.2	57,830	2.6	182	1.1	9,335	2.4	175	2.2
Cal-3	125	177,774	2.2	175,592	4.1	13,856	2.7	172	3.5	2,559	5.2	166	0.3
Cal-4	31.2	40,073	1.7	41,003	1.0	3,542	1.3	171	1.2	750	0.9	159	4.9
Cal-5	7.81	8,793	5.6	9,013	3.0	946	5.2	163	7.1	299	6.8	162	3.1
Cal-6	1.95	2,294	8.1	2,502	3.2	368	3.7	153	5.2	191	5.9	154	5.5
Cal-7	0.49	697	4.5	961	5.5	212	5.4	161	5.4	160	2.6	149	2.5
Cal-8	0	272	6.6	272	6.6	161	4.8	161	4.8	154	5.2	154	5.2


3 Calibration Curve, Assay Range

Calibration curves for tTau, pTau(181) and pTau(231) are shown below, along with a table that includes Hill slopes, limits of detection (LOD), lower limits of quantitation (LLOQ) and upper limits of quantitation (ULOQ).

The LLOD corresponds to a signal at 2.5 standard deviations above the background. LLOQ was assigned as the lowest concentration measured with a CV of 20% or less and recovery within 80%-120%. Similarly, ULOQ was assigned as the highest concentration with a CV of 20% or less and recovery within 80%-120%.

The calibrator is recombinant full-length Tau protein (Tau441); anti-Tau antibodies used in the assays recognize all 6 isoforms of Tau. A non-phosphorylated version of the calibrator was expressed in *E. coli* and used for the tTau assay, while a phosphorylated version was expressed in a mammalian system and used for the tTau assays. 100% phosphorylation was assumed for both the 181 and 231 sites for assigning calibrator concentrations (mass spectrometry indicated at least 60% phosphorylation at each site). The tTau detection limit is 10 fg/ml, which is at least 1000-fold more sensitive than standard immunoassays.

The detection limits for the pTau assays are 166 fg/ml for pTau(181) and 2,663 fg/ml for pTau(231). The assays are likely more sensitive given that the calibrator may not be 100% phosphorylated (further characterization of the calibrator is in process). Compared to pTau assays on the market, the S-PLEX pTau(181) assay is approximately 1000-fold more sensitive and the S-PLEX pTau(231) assay is approximately 35-fold more sensitive (after correcting for calibrator size/weight).



	tTau	pTau(181)	pTau(231)
Hill Slope	0.98	1.05	1.05
LOD, pg/mL: Median (Range)	0.010 (0.080 – 0.012)	0.166 (0.155 – 0.171)	2.66 (2.40 – 2.84)
Lot Specific LLOQ, pg/mL	0.12	0.26	10.0
Lot Specific ULOQ, pg/mL	200	1,733	25,000


Phospho-Tau Assay Specificity

The specificity of the pTau assays was assessed by measuring their cross reactivity to non-phosphorylated and phosphorylated Tau protein. Dilution curves of both forms of calibrator were measured on all three assays. The data confirms that the pTau assays do not recognize non-phosphorylated Tau, while the tTau assay recognizes phosphorylated

and non-phosphorylated tau equivalently.

5 Human Samples

more concentrated in CSF, as expected. the graphs below).



Subject	Sample Type	Statistic	Total Tau	pTau181	pTau231
		Number Tested	20	20	20
	Serum	Median (pg/mL)	19.2	4.95	5.72
	Serum	Range (pg/mL)	18.3 – 45.5	1.09 - 8.86	ND – 8.42
		% Detected	100	20 20 20 9.2 4.95 5.72 -45.5 $1.09 - 8.86$ ND $- 8.42$ 00 100 35 8 11 11 3.1 2.14 7.57 -22.5 $1.12 - 7.45$ ND $- 9.57$ 00 100 36 12 13 13 70 16.7 6.68 -606 $4.77 - 191$ ND $- 7.08$ 00 100 23 20 38 38 5.7 12.1 4.70 -120 $0.776 - 53.2$ ND $- 4.88$ 00 100 18 12 17 17 2.9 3.70 8.49 -51.7 $744 - 24.1$ ND $- 9.99$	
		Number Tested	8	11	11
Nemerale	Plasma	Median (pg/mL)	13.1	2.14	7.57
Normals	Flasina	Range (pg/mL)	8.08 - 22.5	1.12 – 7.45	ND – 9.57
		% Detected	100	100	36
		Number Tested	12	13	13
	CSF	Median (pg/mL)	170	16.7	6.68
	CSF	Range (pg/mL)	71.8 - 606	4.77 -191	ND – 7.08
		% Detected	100	100	23
		Number Tested	20	38	38
	Decled Comm	Median (pg/mL)	25.7	12.1	4.70
Alzheimer's	Pooled Serum	Range (pg/mL)	2.90 - 120	0.776 - 53.2	ND – 4.88
		% Detected	100	100	18
		Number Tested	12	17	17
Domontia	De alad Camera	Median (pg/mL)	22.9	3.70	8.49
Dementia	Pooled Serum	Range (pg/mL)	8.19 – 51.7	744 – 24.1	ND – 9.99
		% Detected	100	100	35



Serum (n=27) and plasma (n=8-11) from healthy donors, serum from individuals with Alzheimer's (n=20-38) and dementia (n=12-17) and cerebral spinal fluid (CSF, n=12-13) were measured on the three tau assays.

Samples were tested neat for the pTau assays and diluted 2-fold for the tTau assay.

Total Tau and pTau(181) were guantifiable in 100% of the samples with some higher samples noted in the diseased groups; tTau is

pTau(231) was below the LLOD in the majority of normal samples (undetectable samples are assigned the LLOD concentration in

6 Spike Recovery

Serum, EDTA plasma and heparin plasma samples (n=4) were spiked with recombinant calibrator at three different concentrations spanning the dynamic range of each assay Percent recovery was calculated by dividing the difference between the measured concentration in the spiked and non-spiked samples by the expected spike concentration. (% Recovery= (Measured Spiked - Measured non-Spiked) / Spike). Average spike recovery for the tTau assay was within 70%-130% in serum and EDTA plasma. The pTau assays recovered within 70%-130% in serum and heparin plasma.

		Total	Tau	pTau	(181)	pTau (231)		
Matrix	Spike Level	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range	
	High Spike	96	86-104	107	87-116	89	62-113	
Serum	Mid Spike	74	60-86	105	86-113	91	69-113	
	Low Spike	83	75-90	105	85-116	92	65-117	
EDTA	High Spike	113	102-118	149	140-158	137	122-160	
Plasma	Mid Spike	96	74-111	144	136-151	138	126-148	
Flasilla	Low Spike	102	87-113	138	135-142	143	131-155	
Honorin	High Spike	55	36-71	112	79-129	89	58-108	
Heparin - Plasma -	Mid Spike	62	40-80	118	80-151	88	58-100	
Flasilla	Low Spike	69	46-88	115	82-134	93	59-109	

Dilution Linearity

Serum, EDTA and heparin plasma samples (n=2) spiked with recombinant calibrator were diluted 2x, 4x, and 8x and measured on all three assays.

The recovery was normalized to the recommended sample dilution level: 2x for tTau and 1x (neat) for pTau assays. Average dilution linearity for serum/plasma samples was within 70%-130% for the tTau and pTau(181) assays. The pTau231 assay recovered ~90% on average in EDTA plasma but showed over-recovery in serum and heparin plasma.

	Dilution	Total Tau			pTau181			pTau231		
Sample Matrix	Dilution Factor	ECL Signal	Concen. (pg/mL)	% Recovery	ECL Signal	Concen. (pg/mL)	% Recovery	ECL Signal	Concen. (pg/mL)	% Recovery
	None	507,707	208	81	33,321	310		19,750	1,736	
Sorum (NI-2)	2x	313,226	257		16,680	319	103	12,619	2,232	129
Serum (N=2)	4x	157,630	260	101	7,486	293	94	7,174	2,551	147
	8x	76,526	253	98	3,796	298	96	3,529	2,503	144
	None	760,475	311	100	45,357	418		32,616	2,845	
EDTA Plasma	2x	380,541	312		19,042	361	87	15,618	2,756	97
(N=2)	4x	182,474	301	96	7,870	307	74	7,314	2,600	91
	8x	81,398	269	86	3,665	288	69	3,452	2,4478	86
	None	410,470	168	68	41,374	382		17,783	1,566	
Heparin Plasma	2x	303,106	249		19,373	368	96	14,466	2,555	163
(N=2)	4x	157,795	260	104	7,803	305	80	7,402	2,631	168
	8x	96,752	320	128	5,833	456	119	3,576	2,537	162

8 Conclusion

Ultrasensitive assays for total Tau and phosphorylated versions of Tau have been developed using MSD's S-PLEX format, with improved sensitivity over standard immunoassay formats. These assays allow quantitation of tTau and pTau181 in serum and plasma, providing a new tool for researching these important biomarkers of neurodegeneration.

MESO SCALE DISCOVERY, MESO SCALE DIAGNOSTICS, MSD, mesoscale.com, www.mesoscale.com, methodicalmind.com, www.methodicalmind.com, DISCOVERY WORKBENCH, MESO, MesoSphere, Methodical Mind, MSD GOLD MULTI-ARRAY, MULTI-SPOT, QuickPlex, ProductLink, SECTOR, RECTOR PR, SECTOR HTS, SULFO-TAG, TeamLink, TrueSensitivity, TURBO-BOOST, TURBO-TAG, N-PLEX, S-PLEX, T-PLEX, V-PLEX, V-PLEX, MSD (design). MSD (luminous design), Methodical Mind (design), 96 WELL SMALL-SPOT (design), 96 WELL 1-, 4-, 7-, 9-, & 10-SPOT (designs), 384 WELL 1- & 4-SPOT (designs), N-PLEX (design), R-PLEX (design), S-PLEX (design), T-PLEX (design), U-PLEX (design), V-PLEX (design), It's All About U, SPOT THE DIFFERENCE, The Biomarker Company, and The Methodical Mind Experience are trademarks and/or service marks owned by or licensed to Meso Scale Diagnostics, LLC. All other trademarks and service marks are the property of their respective owners.

©2020 Meso Scale Diagnostics, LLC. All rights reserved.





